Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease.

Jin Ran, Emory University
Andrew Willment, Emory University
Shivani S. Patel, Medical University of South Carolina
Xiaoyan Sun, Medical University of South Carolina
Mingqing Song, Emory University
Yanci O. Mannery, University of Louisville
Astrid Kosters, Emory University
Craig J. McClain, University of Louisville
Miriam Vos, Emory University

Journal Title: International Journal of Hepatology
Volume: Volume 2014
Publisher: Hindawi Publishing Corporation | 2014, Pages 560620-560620
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1155/2014/560620
Permanent URL: https://pid.emory.edu/ark:/25593/mr43z

Final published version: http://dx.doi.org/10.1155/2014/560620

Copyright information:
© 2014 Ran Jin et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/), which permits distribution, public display, and publicly performance, distribution of derivative works, making multiple copies, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author, copyright and license notices be kept intact.

Accessed October 18, 2019 9:59 PM EDT
Fructose Induced Endotoxemia in Pediatric Nonalcoholic Fatty Liver Disease

Ran Jin, 1 Andrew Willment, 1 Shivani S. Patel, 2 Xiaoyan Sun, 3 Ming Song, 4 Yanci O. Manners, 4 Astrid Kosters, 1 Craig J. McClain, 4, 5 and Miriam B. Vos 1, 6

1 Department of Pediatrics, School of Medicine, Emory University, 2015 Uppergate Drive NE, Atlanta, GA 30322, USA
2 Medical University of South Carolina, Charleston, SC 29425, USA
3 Department of Statistics, Emory University, Atlanta, GA 30322, USA
4 School of Medicine, University of Louisville, Louisville, KY 40202, USA
5 Robley Rex Louisville VAMC, Louisville, KY 40206, USA
6 Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA

Correspondence should be addressed to Miriam B. Vos; mvos@emory.edu

Received 8 May 2014; Revised 9 September 2014; Accepted 10 September 2014; Published 28 September 2014

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease and is estimated to affect 40% of obese adolescents in the United States [1]. In adults with NAFLD, circulating endotoxin (lipopolysaccharide or LPS) has been reported to be elevated [2, 3]. Endogenous antibodies against endotoxin are also increased in adults with biopsy-proven nonalcoholic steatohepatitis (NASH), suggesting chronic exposure [4]. However, studies in the pediatric population remain scarce and it is less clear whether or not endotoxin is an important mediator of NAFLD in the early forms of the disease as seen in children. A study by Alisi et al. found increased endotoxin levels among children with NAFLD compared to healthy weight controls [5], but endotoxin could also be associated with obesity per se [6, 7], thus warranting further examination.

Animal models have demonstrated that a high-fructose regimen causes increased portal blood endotoxin levels and hepatic steatosis [8, 9]. In mice, reduction of endotoxin using oral antibiotics improved both hepatic steatosis and inflammation [9]. In spite of the growing body of evidence associating fructose with endotoxemia and the metabolic syndrome from preclinical studies, data from human studies on fructose and endotoxin are scarce. In particular, adolescents are an important group to focus on because of their high intake of fructose [10] and the increased prevalence of NAFLD [1].
In the current study, we utilized stored samples from three separate cohorts and sought to answer two distinct questions: (1) are endotoxin levels increased in adolescents with NAFLD (as shown in adults)? (2) Is there a link between fructose consumption and endotoxin levels in adolescents with NAFLD?

2. Methods

2.1. Subjects and Study Design. This analysis utilized data and samples from a cross-sectional study and two prospective studies of fructose consumption in adolescents with and without NAFLD. The primary outcomes have been previously reported by our research group [11, 12]; however, endotoxin levels have not been evaluated and associated with NAFLD. All studies were approved by the Emory University and Children’s Healthcare of Atlanta IRB, and written informed consent (parental consent obtained for subjects <18 years) and assent (when applicable) were obtained for each subject prior to initiation of the study.

Cohort 1 was comprised of 43 Hispanic, obese (BMI z-score > 95th percentile for age and gender) adolescents (aged 11–18 years), who had self-reported high consumption of sweet beverages (at least 3 servings of 12 fl oz per day on average). Because both Hispanic ethnicity [13] and high intake of sweet beverages [14] have been reported to be risk factors for hepatic steatosis, we were able to recruit a group of adolescents in this cohort who were likely to have increased risk of significant steatosis but who had not been previously diagnosed or treated for NAFLD. The subjects and exclusion criteria were carefully described in a previously published article [12]. All recruited participants underwent magnetic resonance spectroscopy (MRS) to quantify their hepatic fat. Subjects with hepatic fat > 5% were considered as having steatosis [15] (n = 32), or they were classified as obese controls (n = 11) if MRS-documented hepatic fat < 5%.

Cohort 2 included a total of 15 adolescents, with 8 being biopsy-proven NAFLD (7 were NASH) and 7 being matched healthy controls. The study design was described elsewhere in detail [11]. Briefly, it was a 24-hour, randomized, crossover feeding study and participants were randomized to either fructose or glucose beverages (3 servings of 12 fl oz bottles each day) to replace their usual consumption of sweet beverages. These beverages contained 33 grams of sugar (standard amount of sugar in a typical soda) in the form of either glucose or fructose, matched for color and flavoring (Power Brands, Beverly Hills, CA). Follow-up visits were scheduled at 2 and 4 weeks after the initiation of randomization to monitor body weight and hepatic fat. Fasting blood samples were also collected for the evaluation of metabolic parameters. At the time of the endotoxin study, a total of 16 subjects had sufficient, nonhemolized blood samples available from baseline, 2 and 4 weeks.

2.2. Measurement of Hepatic Fat. Hepatic fat was assessed by MRS using a rapid 15 sec acquisition technique obtained during a single breath hold [16]. The sequence is constructed from five concatenated echoes using a fixed set of echo times (TE) (12, 24, 36, 48, and 72 ms), with each echo having a repetition time (TR) = 3000 ms, voxel = 3 × 3 × 3 cm³, 1024 points, and 1200 Hz bandwidth. Data were exported off-line for automatic processing with in-house software (Matlab, MathWorks, Natick, MA). Water and lipid magnitude spectra were analyzed by determining the area under the curve (AUC) corresponding to a user-defined frequency range surrounding the corresponding water/lipid peaks (water peak: 4.6 ppm; lipid peak: 1.3, 2.0 ppm). The integrated magnitude signals at each TE were fit to exponential T2 decay curves, whereby the equilibrium signal (M0) and the relaxation rate (R2 = 1/T2) were determined by least-squares regression approximation. Using M0 for water and lipid, the T2-corrected hepatic lipid fraction was calculated from % hepatic lipid = M0lipid/(M0lipid + M0water).

2.3. Laboratory Measurement. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were examined by the Emory University Hospital clinical laboratory. Plasma glucose, insulin, and high sensitivity C-reactive protein (hs-CRP) were measured with immunoturbidimetric methods (Sekisui Diagnostics, Exton, PA) using AU480 chemistry analyzer (Beckman Coulter), by the Emory Lipid Research Laboratory. Plasma tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) were determined with multianalyte chemiluminescence detection using Luminox xMap technology (Millipore Corporation, St. Louis, MO). Endotoxin levels were evaluated by colorimetric assay. Plasma samples were diluted 2-fold in pyrogen-free water, mixed, and heated at 75 °C for 10 min to remove nonspecific inhibitors of endotoxin. Samples were allowed to cool to room temperature before the colorimetric assay using the limulus amoebocyte lysate (LAL) kit (Lonza Walkersville, MD). Standards and samples were incubated with LAL for 10 min at 37 °C followed by 6 min incubation with colorimetric substrate. The reaction was stopped with 25% acetic acid, and the absorbance was read at 405 nm.
2.4. Insulin Resistance Index. Insulin resistance was assessed by the homeostasis model of assessment—insulin resistance (HOMA-IR), which was calculated by glucose (mmol/L) × insulin (mU/L)/22.5 at fasting state.

2.5. Statistical Analyses. Statistical analyses were performed using SAS 9.1. Results in tables were expressed as mean (SD) unless indicated otherwise. Data were examined for normality and equal variance prior to any analyses. Independent two sample t-tests or alternatively Mann-Whitney tests (if not normally distributed) were used for comparison between adolescents with and without hepatic steatosis and between adolescents randomized to glucose or fructose beverage groups. Multiple linear regression models were performed to adjust metabolic parameters including BMI z-score, HOMA-IR, and hs-CRP. Paired t-tests were conducted to determine the significance of percent change in endotoxin levels at weeks 2 and 4, as compared to baseline. The correlations of endotoxin were examined using bivariate correlation tests. In the feeding study, the 9-hour (9-h) and 23-hour (23-h) incremental areas under the curve (IAUC) were calculated for endotoxin by using the trapezoidal method, and independent comparisons were performed for each single time point between NAFLD and non-NAFLD subjects.

3. Results

3.1. Cross-Sectional Comparison of Fasting Endotoxin Level (Cohort 1). Anthropometrics and laboratory parameters for the 32 obese adolescents with hepatic steatosis and the 11 obese adolescents without hepatic steatosis are reported in Table 1. There were no significant differences in age, gender, body weight, BMI z-score, and hs-CRP between the two groups. Adolescents with hepatic steatosis (>5% by MRS) had increased ALT (P = 0.021), AST (P < 0.001), fasting insulin (P = 0.010), and insulin resistance as assessed by HOMA-IR (P = 0.013) compared with obese control adolescents. The plasma concentration of endotoxin in obese adolescents without hepatic steatosis averaged 1.22 ± 0.30 EU/mL (mean ± SD, ranging from 0.64 to 1.61 EU/mL), while in participants with steatosis, the mean endotoxin level was significantly increased to 1.54 ± 0.52 EU/mL (mean ± SD, ranging from 0.85 to 2.83 EU/mL) (P = 0.019) (Figure 1(a)). In multiple linear regression models, we found that the difference in endotoxin levels between subjects with and without steatosis remained significant after adjusting for BMI z-score (P = 0.036) and for hs-CRP (P = 0.042), respectively, but was blunted after the adjustment for HOMA-IR (P = 0.068) and for the cluster of HOMA-IR, BMI z-score, and hs-CRP (P = 0.056).

We further examined TNF-α and MCP-1 levels on a subgroup of subjects who had sufficient blood samples available. We found that adolescents with steatosis had a trend towards higher TNF-α (mean ± SD: 5.46 ± 1.89 versus 4.42 ± 2.28 pg/mL, P = 0.18) and significantly increased MCP-1 (mean ± SD: 150 ± 46.4 versus 126 ± 18.5 pg/mL, P = 0.034) compared to their obese controls (Figures 1(b) and 1(c)) and that plasma endotoxin amount was positively correlated with TNF-α (r = 0.471, P = 0.006), MCP-1 (r = 0.337, P = 0.047), and HOMA-IR (r = 0.381, P = 0.013).

3.2. Endotoxin Response to Acute Feeding Challenge (Cohort 2). Next, we evaluated postprandial endotoxin levels in samples from a group of 15 adolescents, 8 of whom had histologically confirmed NAFLD and 7 matched healthy adolescents. Their baseline characteristics are summarized in Table 2. In response to fructose beverages (consumed with meals), adolescents with NAFLD had an acute increase of plasma endotoxin levels after 1, 3, and 5 hours (P < 0.05 for all) compared to non-NAFLD subjects. This resulted in an elevation of 9-h IAUC of postprandial endotoxin in NAFLD compared to their healthy controls (mean ± SE: 6.85 ± 1.49 versus 2.50 ± 0.87, P = 0.026). The biggest differences were seen after breakfast and lunch and less variation was seen overnight; thus their 23-h IAUC comparison (mean ± SE: 15.11 ± 3.83 versus 10.19 ± 4.23, P = 0.23) did not reach statistical significance (Figure 2(a)). In contrast, no significant difference of postprandial endotoxin in response to glucose beverages (consumed with meals) was observed between adolescents with and without NAFLD (Figure 2(b)).

3.3. Endotoxin Response to 4-Week Beverage Trial (Cohort 3). Finally, we measured endotoxin in samples from adolescents with NAFLD who participated in a 4-week study of fructose beverages compared to glucose beverages. The baseline characteristics of the 16 adolescents with hepatic steatosis who participated in the 4-week beverage trial are presented in Table 3. There were no significant differences in age, gender, weight, glycemic status, and lipid profile between the two groups. Compared to baseline, after drinking 3 study-provided fructose beverages per day, participants had significantly increased fasting plasma endotoxin levels at 2 weeks (mean ± SD: 1.21 ± 0.29 versus 1.45 ± 0.50 EU/mL, P = 0.018) and a trend for increased endotoxin at 4 weeks (mean ± SD: 1.21 ± 0.29 versus 1.47 ± 0.53 EU/mL, P = 0.088), while adolescents who consumed glucose beverages did not have increased endotoxin levels (mean ± SD: 1.61 ± 0.69, 1.39 ± 0.38, and 1.55 ± 0.55 EU/mL at weeks 0, 2, and 4, resp.) (Figure 3).

4. Discussion

Children and adolescents are an important group in which one can study the mechanisms leading to NAFLD because they have an early, possibly more aggressive form of the disease [17]. In addition, they are less likely to have other chronic diseases which could alter gut permeability as well as endotoxin transfer and/or clearance. Through these analyses, we found that obese adolescents with elevated hepatic steatosis had increased plasma endotoxin levels compared to those with normal hepatic fat (<5% by MRS) even after multiple adjustments for metabolic markers, suggesting a possible role for endotoxin in the mechanism of pediatric NAFLD. Second, we observed that adolescents with NAFLD (mostly NASH) had elevated postprandial endotoxin compared to healthy individuals. Finally, in a 4-week randomized controlled trial,
Table 1: Anthropometrics and laboratory parameters of the 32 adolescents with hepatic steatosis and the 11 obese controls at fasting state: study cohort 1.

<table>
<thead>
<tr>
<th>Parameters, mean (SD)</th>
<th>Obese controls (&lt;5% by MRS, n = 11)</th>
<th>Subjects with steatosis (&gt;5% by MRS, n = 32)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>14.3 (1.85)</td>
<td>13.7 (2.65)</td>
<td>0.443</td>
</tr>
<tr>
<td>Male (n, %)</td>
<td>4 (36.4)</td>
<td>13 (40.6)</td>
<td>0.803</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>82.9 (21.5)</td>
<td>80.5 (14.9)</td>
<td>0.967</td>
</tr>
<tr>
<td>BMI z-score</td>
<td>2.00 (0.22)</td>
<td>2.17 (0.37)</td>
<td>0.129</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>17.8 (7.60)</td>
<td>49.7 (89.5)</td>
<td>0.021</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>21.9 (3.99)</td>
<td>68.2 (180)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hepatic fat (%)</td>
<td>3.87 (0.62)</td>
<td>11.2 (5.27)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>5.13 (0.89)</td>
<td>5.18 (0.90)</td>
<td>0.978</td>
</tr>
<tr>
<td>Insulin (mU/L)</td>
<td>18.2 (6.69)</td>
<td>36.2 (30.5)</td>
<td>0.010</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>4.06 (1.31)</td>
<td>8.79 (9.13)</td>
<td>0.013</td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>3.17 (3.44)</td>
<td>4.98 (5.92)</td>
<td>0.278</td>
</tr>
</tbody>
</table>

BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HOMA-IR: homeostatic model assessment for insulin resistance, calculated as fasting glucose (mmol/L) × insulin (mU/L)/22.5; hs-CRP: high sensitivity C-reactive protein.

Table 2: Baseline characteristics of the 8 adolescents with biopsy-proven NAFLD and the 7 healthy controls: study cohort 2.

<table>
<thead>
<tr>
<th>Parameters, mean (SD)</th>
<th>non-NAFLD (n = 7)</th>
<th>NAFLD (n = 8)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>13.7 (2.22)</td>
<td>13.0 (2.73)</td>
<td>0.315</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>5 (71.4)</td>
<td>8 (100)</td>
<td>0.104</td>
</tr>
<tr>
<td>BMI z-score</td>
<td>0.18 (0.65)</td>
<td>2.29 (0.38)</td>
<td>0.001</td>
</tr>
<tr>
<td>Hepatic fat (%)</td>
<td>1.02 (1.18)</td>
<td>22.0 (6.16)</td>
<td>0.001</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>14.6 (2.51)</td>
<td>130 (63.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>23.4 (4.30)</td>
<td>79.6 (40.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>5.53 (0.40)</td>
<td>5.32 (1.06)</td>
<td>0.487</td>
</tr>
<tr>
<td>Insulin (mU/L)</td>
<td>9.67 (12.4)</td>
<td>42.7 (27.7)</td>
<td>0.005</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.27 (2.70)</td>
<td>10.2 (6.99)</td>
<td>0.016</td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>0.25 (0.49)</td>
<td>2.95 (3.33)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HOMA-IR: homeostatic model assessment for insulin resistance, calculated as fasting glucose (mmol/L) × insulin (mU/L)/22.5; hs-CRP: high sensitivity C-reactive protein.

Table 3: Baseline characteristics of participants enrolled in the 4-week beverage trial: study cohort 3.

<table>
<thead>
<tr>
<th>Parameters, mean (SD)</th>
<th>Fructose (n = 8)</th>
<th>Glucose (n = 8)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>14.6 (2.50)</td>
<td>13.3 (2.32)</td>
<td>0.273</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>3 (37.5)</td>
<td>4 (50.0)</td>
<td>0.614</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>86.1 (13.3)</td>
<td>81.3 (15.9)</td>
<td>0.521</td>
</tr>
<tr>
<td>BMI z-score</td>
<td>2.32 (0.56)</td>
<td>2.01 (0.26)</td>
<td>0.184</td>
</tr>
<tr>
<td>Hepatic fat (%)</td>
<td>14.5 (5.73)</td>
<td>12.1 (4.82)</td>
<td>0.382</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>35.1 (20.5)</td>
<td>31.3 (18.6)</td>
<td>0.698</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>32.1 (9.76)</td>
<td>32.9 (7.45)</td>
<td>0.865</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>161 (111)</td>
<td>175 (58.5)</td>
<td>0.768</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)</td>
<td>166 (28.8)</td>
<td>170 (48.8)</td>
<td>0.836</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>106 (32.5)</td>
<td>105 (38.6)</td>
<td>0.967</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>45.1 (9.84)</td>
<td>45.0 (9.83)</td>
<td>0.986</td>
</tr>
<tr>
<td>FFA (mmol/L)</td>
<td>0.97 (0.24)</td>
<td>1.16 (0.51)</td>
<td>0.342</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>5.46 (0.85)</td>
<td>4.97 (1.59)</td>
<td>0.461</td>
</tr>
<tr>
<td>Insulin (mU/L)</td>
<td>30.0 (13.7)</td>
<td>31.4 (30.5)</td>
<td>0.906</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>7.17 (3.03)</td>
<td>7.23 (8.28)</td>
<td>0.985</td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>4.22 (3.03)</td>
<td>3.16 (2.54)</td>
<td>0.242</td>
</tr>
</tbody>
</table>

ALT: alanine aminotransferase; AST: aspartate aminotransferase; LDL: low-density lipoprotein; HDL: high-density lipoprotein; FFA: free fatty acid; HOMA-IR: homeostatic model assessment for insulin resistance index, calculated as fasting glucose (mg/dL) × insulin (µU/L)/405; hs-CRP: high sensitivity C-reactive protein.
Figure 1: Obese adolescents with hepatic steatosis (>5% by MRS) had increased (a) plasma endotoxin levels, (b) plasma TNF-α levels, and (c) plasma MCP-1 levels as compared to obese adolescents without significant steatosis (hepatic fat < 5% by MRS); *P < 0.05.

Figure 2: Postprandial plasma endotoxin levels in response to (a) fructose and (b) glucose beverages given with breakfast, lunch, and dinner. The solid line represents 7 children without NAFLD and the dashed line shows the response in 8 children with biopsy-proven NAFLD. Baseline values were set as reference (1.0) and the following time points represent the ratio to baseline. *P < 0.05 when comparing NAFLD and non-NAFLD subjects at given time point.
we found a trend for increased fasting plasma endotoxin after exposure to fructose drinks.

A previous study by Alisi et al. suggested that endotoxin levels were increased in pediatric NAFLD compared to healthy weight subjects [5]. We compared endotoxin levels in a weight and ethnicity matched cohort because obesity has been indicated to be associated with dysfunction/disturbance of the gastrointestinal barrier and consequently increased entry of endotoxin into the circulation [18, 19]. It has also been shown that diabetic patients appear to have higher endotoxin amounts suggesting a correlation between endotoxin and insulin resistance [20]. In the current study, by adjusting for BMI, insulin resistance, and inflammatory marker hscrp, we found that the elevation of endotoxin appears to be strongly related to the presence of hepatic steatosis. Both endotoxin and its resultant inflammatory perturbation appear to trigger hepatic and peripheral insulin resistance [21]. Agwuobie et al. published data using euglycemic clamps that demonstrated hepatic insulin resistance following LPS administration [22], and Mehta et al. reported a 35% decrease in insulin sensitivity induced by endotoxemia [23]. Cytokines such as TNF-α can inhibit insulin receptor signaling and target insulin receptor substrate proteins for degradation [24]. Furthermore, endotoxin is also known to markedly induce MCP-1 [25] which can recruit the C-C motif chemokine receptor-2 (CCR2)-expressing monocytes in adipose tissue, and CCR2 associates adipose tissue inflammation and systemic insulin resistance [26]. However, given the fact that NAFLD (particularly in its advanced form NASH) has a nearly universal interrelationship with obesity, insulin resistance, and inflammation, it is difficult to distinguish between the effects of endotoxemia on hepatic fat (NAFLD) and its coexisting metabolic morbidities.

The idea that fructose induced endotoxin might contribute to NAFLD has been studied in animal models and adults, but little data were previously available in children. In a fructose fed mouse model, antibiotics reduced fructose induced endotoxin in the portal blood and improved hepatic steatosis and inflammation [9]. Subsequent studies demonstrated that endotoxin stimulates the innate immune system via toll-like receptor 4 (TLR4) to increase inflammation in the liver [8]. In mechanism studies, increased endotoxin release from the gut can activate TLR4 to stimulate myeloid differentiation factor 88 (MyD88) [27]. This interaction of TLR4 and MyD88 triggers the downstream signaling cascade leading to the activation of the nuclear factor-κB (NF-κB) pathway, further releasing inflammatory cytokines such as TNF-α and IL-6, which, in turn, can result in liver injury [27]. Furthermore, animals with NAFLD have been shown to have partial loss of the tight junction protein, occluden-1, contributing to increased intestinal permeability and translocation of intestinal endotoxin [28]. Fructose could make this worse because tight junction proteins have been shown to be markedly lower in mice chronically exposed to fructose in comparison to water-fed controls [29]. Supporting this, mice fed with significantly greater amounts of fructose had elevated plasma endotoxin levels and higher hepatic expression of genes of the TLR-4-dependent signaling cascade [30].

To evaluate the above effects in pediatric NAFLD, we studied endotoxin levels in two situations: after acute consumption of fructose and after weeks of fructose beverages. Both NAFLD and non-NAFLD subjects had an acute elevation of postprandial endotoxin concentrations after fructose beverages (consumed with meals) in the 24-hour acute feeding challenge, but there was a significantly higher response observed in adolescents with NAFLD. This increased susceptibility in NAFLD might be explained by increased gut permeability, disruption of intestinal tight junctions, and possible alterations in the microbiome as indicated in adults [28, 31]. A recent study by Giorgio et al. further reported increased intestinal permeability in children with NAFLD [32]. Alternatively, the increased endotoxin could be due to impaired Kupffer cell function. Normally, endotoxin released from the gut is cleared rapidly on first pass by Kupffer cells to prevent its escape into the systemic circulation. In NAFLD, this hepatic clearance may be disturbed and insufficient [33] and could be responsible for the increased level of circulating endotoxin.

Because we saw postprandial increases in the acute feeding challenge study, we evaluated endotoxin in a longer, calorie-matched, randomized controlled beverage trial in adolescents with hepatic steatosis comparing fructose beverages to glucose beverages. We found that 4 weeks of glucose beverages did not further exacerbate endotoxin levels, while continuous provision of fructose beverages resulted in elevation of endotoxin after just 2 weeks with a trend towards an increase at 4 weeks (no longer significant because of subject variability). A pilot study in adults also showed a decrease in endotoxin in response to fructose reduction, although over 6 months. In that study, subjects with NAFLD...
who consumed 50% less fructose compared to baseline had significantly lower levels of endotoxin as well as hepatic lipid contents [34]. However, causality could not be proven because the subjects also lost weight. In our trial, the body weights remained stable from baseline to the end of the intervention. Putting our data together with the previous studies, it appears possible that when subjects are chronically exposed to a high fructose environment, endotoxemia and subsequent activation of inflammatory cytokines occur and promote insulin resistance in the liver thus contributing to NAFLD.

Strengths of our studies include (1) the well-matched cohorts allowing us to isolate the effect of NAFLD and examine its associations; (2) the precise measurement of hepatic steatosis by MRS; and (3) the utilization of an inpatient feeding study methodology conducted in a metabolic unit. Importantly, in both cohorts 2 and 3, the experiments were randomized, controlled tests of fructose administration in comparison to a calorically matched beverage (glucose drinks). This methodology provides the strongest evidence that fructose is possibly causing the differences seen.

There were several limitations in these studies. Our subjects in cohort I are Hispanic-American adolescents; thus our findings may not be generalizable to other racial and ethnic groups, particularly African-American children, who develop NAFLD less often. In our acute feeding challenge study (cohort 2), endotoxemia peaked rapidly after meals and normalized overnight. Because we measured blood every two hours, we may have missed the true peak level(s) of endotoxin. Further, we were unable to determine if endotoxin was elevated because of slower clearance or increased translocation into the bloodstream and whether this increase of endotoxin was caused by the presence of hepatic steatosis or its closely associated metabolic perturbations. In the 4-week randomized controlled trial (cohort 3), it is possible that participants made other changes to their diets in response to the research beverages even though they were requested to keep their diet pattern. Finally, the study did not include stool so we were unable to assess if the endotoxin changes seen were secondary to a change in the microbiota.

In conclusion, we demonstrated that exposure to high fructose both acutely (postprandial) and chronically (2 weeks) is associated with an increase of circulating endotoxin in adolescents with NAFLD, and we also demonstrated correlations of endotoxin with markers of insulin resistance and inflammation. Fructose reduction is a feasible side-effect-free strategy for patients with NAFLD to prevent disease progression. However, further studies will be necessary to prove the therapeutic and possibly preventive benefits of fructose reduction.

**Conflict of Interests**

All authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

The authors thank all of the patients and their families for generously giving their time. In addition, these studies would not have been possible without the tireless dedication of the research coordinators, Nicholas Raviele, Xiromara Hinson, Rebecca Cleeton, and Jessica Cruz. This work is supported by the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases Grant K23 DK080953 (Vos); NIH: RO1AA018016, IR01AA018869, IU01AA021901, IU01AA021893-01 (McClain); VA: BX000350 Merit Award (McClain); University of Louisville Clinical and Translational Sciences Pilot Grant Program (McClain). The authors’ responsibilities are as follows: Miriam B. Vos designed research, supervised study, wrote parts of the paper, and has primary responsibility for final content; Ran Jin performed part of laboratory measurements, analyzed and interpreted the data, and wrote parts of the paper; Andrew Willment, Ming Song, and Yanci O. Mannery performed part of laboratory measurements; Shivani S. Patel contributed to data analyses; Xiaoyan Sun performed and examined the statistical analyses; Astrid Kosters and Craig J. McClain assisted with data interpretation and contributed to the development of the paper.

**References**


